Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G C Viberti

Showing results (21-30 of 152) with videos related to

Pageof 16
Sort By:
Diabetes|May 2, 2007
Comment on: Boden et al. (2007) Combined use of rosiglitazone and fenofibrate in patients with type 2 diabetes: prevention of fluid retention: Diabetes 56:248-255J Karalliedde, G C Viberti
Diabetes Care|November 1, 1991
Introduction: hypertension and diabetes. Critical combination for micro- and macrovascular diseaseG C Viberti, J Messent
Journal of the Royal College of Physicians of London|September 27, 2000
Proteinuria in diabetesS Thomas, G C Viberti
Journal of Clinical Pathology|November 1, 1981
Genesis and evolution of diabetic nephropathyH Keen, G C Viberti
Diabete & Metabolisme|January 1, 1989
Hypertension and microalbuminuria as predictors of diabetic nephropathyS L Jones, G C Viberti
Journal of Endocrinological Investigation|March 4, 2000
Is it possible to predict diabetic kidney disease?S M Thomas, G C Viberti
Kidney International. Supplement|August 20, 2005
Cardiovascular risk in diabetic kidney disease: a model of chronic renal diseaseS M Thomas, G C Viberti
Diabetologia|March 1, 1985
Risk of nephropathy in diabetes mellitus: problems of methodology and terminologyR J Jarrett, G C Viberti
Advances in Experimental Medicine and Biology|January 1, 1989
Diabetic nephropathy: pathophysiology, clinical course and susceptibilityG C Viberti, J D Walker
Journal of Diabetes and Its Complications|July 1, 1994
Strategies for the prevention of diabetic kidney disease: early antihypertensive treatment or improved glycemic control?D J Barnes, G C Viberti
Pageof 16

Showing results (21-30 of 152) with videos related to

Sort By:
Pageof 16
Diabetes|May 2, 2007
Comment on: Boden et al. (2007) Combined use of rosiglitazone and fenofibrate in patients with type 2 diabetes: prevention of fluid retention: Diabetes 56:248-255J Karalliedde, G C Viberti
Diabetes Care|November 1, 1991
Introduction: hypertension and diabetes. Critical combination for micro- and macrovascular diseaseG C Viberti, J Messent
Journal of the Royal College of Physicians of London|September 27, 2000
Proteinuria in diabetesS Thomas, G C Viberti
Journal of Clinical Pathology|November 1, 1981
Genesis and evolution of diabetic nephropathyH Keen, G C Viberti
Diabete & Metabolisme|January 1, 1989
Hypertension and microalbuminuria as predictors of diabetic nephropathyS L Jones, G C Viberti
Journal of Endocrinological Investigation|March 4, 2000
Is it possible to predict diabetic kidney disease?S M Thomas, G C Viberti
Kidney International. Supplement|August 20, 2005
Cardiovascular risk in diabetic kidney disease: a model of chronic renal diseaseS M Thomas, G C Viberti
Diabetologia|March 1, 1985
Risk of nephropathy in diabetes mellitus: problems of methodology and terminologyR J Jarrett, G C Viberti
Advances in Experimental Medicine and Biology|January 1, 1989
Diabetic nephropathy: pathophysiology, clinical course and susceptibilityG C Viberti, J D Walker
Journal of Diabetes and Its Complications|July 1, 1994
Strategies for the prevention of diabetic kidney disease: early antihypertensive treatment or improved glycemic control?D J Barnes, G C Viberti
Pageof 16